Restoring the gut ecology
behind metabolic health.

Amara develops standardized ecological therapeutics from precision-fermented plant matrices — beginning with physician-supervised support for GLP-1 tolerability, gut-metabolic resilience, and long-term metabolic health.

Category
Ecological therapeutic
Substrate
Plant matrix
Architecture
Multi-kingdom
First program
Amara Restore
02The opportunity
N=5 upstream systems

The GLP-1 era revealed a gut-restoration gap.

These synthetic GLP-1 drugs have transformed metabolic medicine. But many patients still struggle with GI side effects, discontinuation, weight regain after stopping, and the broader metabolic dysfunction that extends beyond any single receptor pathway.

Amara is building ecological therapeutics designed to support the upstream gut ecosystem involved in metabolic health.

01
Microbial metabolism
02
Gut-hormone tone
03
Barrier function
04
Bile-acid signaling
05
Nutrient-response physiology
03Featured program
In development · Pre-clinical
Amara Restore — multi-kingdom fermentation matrix

AMARA
Restore.

A precision multi-kingdom fermentation plant matrix designed for metabolic care.

It is not
  • A probiotic.
  • Kombucha.
  • A meal replacement.
  • A single-ingredient supplement.
It is

A standardized ecological matrix created from selected plant substrates and controlled bacterial guilds, yeast guilds, and fungi — designed to generate gut-relevant metabolites, support microbial cross-feeding, and improve metabolic resilience.

Initial focus
  • GLP-1 adjunct support
  • Gut tolerability
  • Prediabetes
  • Weight loss
  • Long-term maintenance
04Method
Stage 01 → 02 → 03

A three-stage protocol — from structured plant substrates to standardized productization.

Stage 01

Structured plant substrates.

Plant and grain matrices selected for fiber architecture, resistant starch, polyphenols, and fermentable carbohydrates. First program: banana, millet, sorghum.

Stage 02

Precision ecological fermentation.

Bacteria, yeasts, and fungi are guided through controlled fermentation to transform the substrate into a more biologically active ecological matrix.

Stage 03

Standardized clinical productization.

Each product is being developed for reproducibility, batch characterization, safety, and use in real-world metabolic care.

05Mechanisms
5 upstream systems

Most metabolic drugs activate one receptor. We design matrices that may support multiple upstream systems at once.

  1. Mech 01
    Gut hormone tone.
    Supporting endogenous incretin and satiety-related signaling.
  2. Mech 02
    Microbial metabolites.
    Supporting short-chain fatty acid ecology and gut microbial function.
  3. Mech 03
    Gut barrier integrity.
    Supporting the intestinal barrier involved in inflammation and metabolic health.
  4. Mech 04
    Bile-acid signaling.
    Engaging gut-liver pathways linked to glucose, lipids, and incretin biology.
  5. Mech 05
    Metabolic resilience.
    Supporting healthier responses to meals, glucose dynamics, and long-term maintenance.
06Evidence roadmap
Stages i → iv · pre-clinical → clinical

Built for clinical translation, with a clear evidence roadmap.

Stage i
Batch
Stage ii
Mechanism
Stage iii
Pilot
Stage iv
Clinical

Batch reproducibility.

Metabolomics, organic acids, microbial fingerprints, pH, sugars, polyphenols, and fermentation profiles.

Mechanistic validation.

Gut barrier, microbial ecology, bile acids, SCFAs, and incretin-relevant signaling.

Human pilot studies.

CGM, GI symptom scores, tolerability, adherence, glycated albumin, stool markers, and patient-reported outcomes.

Clinical partnerships.

Physician-supervised pilots with obesity, metabolic-health, functional GI, and food-as-medicine partners.

07Audiences
3 channels · 1 system

Built alongside the people delivering metabolic care.

01
For clinicians

Practices delivering supervised metabolic care.

Obesity medicine, metabolic health, endocrinology, gastroenterology, and functional medicine practices interested in supervised metabolic protocols.

Obesity medicineMetabolic healthEndocrinologyGastroenterologyFunctional medicine
02
Channel partners

Organizations building differentiated metabolic-health programs.

Clinics, telehealth platforms, food-as-medicine programs, payers, and care organizations.

03
Patients

People in active metabolic care.

People working on weight, blood sugar, GLP-1 therapy, gut health, or long-term metabolic maintenance.

08Team
4 officers · 3 advisors

Amara brings together expertise in computational biology, ecological fermentation, clinical translation, and metabolic science.

Officers
Scientific Advisors
VN
Founder & CEO
Dr. Vivek Nandur
Computational biology. Developed the ecological-therapeutics thesis.
BB
Chief Product Officer
Brandon Boldt
10+ years production-scale ecological fermentation. Translates insights to manufactured products.
MH
Chief Legal Officer
Mikey Harrell
Early-stage and scaled operator (Cash App, BlockFi). Regulatory and commercialization pathway design.
CN
Chief Operating Officer
Cori Nandur
10+ years agtech operations. Scales systems into real-world production.
AA
Scientific Advisor
Dr. Athena Aktipis
Arizona State University.
RD
Scientific Advisor
Dr. Robert Dudley
University of California, Berkeley.
NG
Scientific Advisor
Dr. Ned Gvozdic
Florida Gulf Coast University.